Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ILK | Q13418 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ESRRB | O95718 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140656 | 0.86 | HTT (0.56) | DYRK1ACA2APPMAPTHTT | |
| SCHEMBL29409281 | 0.86 | HTT (0.56) | DYRK1ACA2APPMAPTHTT | |
| Phosphoric Acid SCHEMBL8165785 | 0.79 | HTT (0.49) | DYRK1ACA2APPMAPTHTT | |
| SCHEMBL25137597 | 0.79 | MAPT (0.53) | CA2APPKDM4ENPC1MAPT | |
| SCHEMBL30874492 | 0.79 | DYRK1A (0.49) | DYRK1AKDM4ENPC1MAPTRAB9A | |
| SCHEMBL2251354 | 0.79 | DYRK1A (0.50) | DYRK1AKDM4ENPC1MAPTRAB9A | |
| SCHEMBL9796864 | 0.78 | PSMB8 (0.44) | DYRK1AAPPNPC1MAPTRAB9A | |
| SCHEMBL30874473 | 0.76 | NPC1 (0.45) | DYRK1AAPPKDM4ENPC1RAB9A | |
| SCHEMBL31215568 | 0.76 | RIPK1 (0.52) | DYRK1ACA2APPNPC1MAPT | |
| SCHEMBL28090972 | 0.75 | CA2 (0.56) | DYRK1ACA2APPKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239787-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-07-18 | — | — | US | disclosed |
| US-20240239787-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-07-18 | — | — | US | disclosed |
| CN-118126061-A | Block precursor for in-situ generation PROTAC of responsiveness in tumor and application thereof | 浙江工业大学 | 2024-06-04 | — | — | CN | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-2346956-B1 | ACTIVATORS FOR TWO PART CYANOACRYLATE ADHESIVES | Henkel IP & Holding GmbH (DE) | 2017-12-06 | — | — | EP | disclosed |
| US-9643985-B2 | PCL compounds, compositions, and methods of use thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643985-B2 | PCL compounds, compositions, and methods of use thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-20150376680-A1 | PCL Compounds, Compositions, And Methods Of Use Thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2015-12-31 | — | — | US | disclosed |
| US-20150376680-A1 | PCL Compounds, Compositions, And Methods Of Use Thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2015-12-31 | — | — | US | disclosed |
| WO-2014127360-A1 | PCL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-08-21 | — | — | WO | disclosed |
| US-6130217-A | ANTITUMOR | PFIZER INC (US) | 2000-10-10 | — | — | US | disclosed |
| WO-1994022846-A1 | COMPOUNDS ENHANCING ANTITUMOR ACTIVITY OF OTHER CYTOTOXIC AGENTS | PFIZER INC. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376680-A1 | PCL Compounds, Compositions, And Methods Of Use Thereof | GPX4, PRDX3, LPO | DYRK1A 4635/4885CA2 2958/4885APP 2314/4885 |
| US-20240239787-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | BRIX1, TP53, XPOT | DYRK1A 4755/4885CA2 4310/4885APP 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.